$0.46
+0.01 (+1.56%)
Open$0.45
Previous Close$0.45
Day High$0.49
Day Low$0.45
52W High$1.53
52W Low$0.34
Volume—
Avg Volume3.89M
Market Cap124.51M
P/E Ratio—
EPS$-0.49
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+3,243.6% upside
Current
$0.46
$0.46
Target
$15.22
$15.22
$10.64
$15.22 avg
$24.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.65M | 3.11M | 180.17M |
| Net Income | -72,981,270 | -55,957,695 | 5.71M |
| Profit Margin | -2,003.6% | -1,903.4% | 3.2% |
| EBITDA | -219,933,100 | -178,000,038 | 9.37M |
| Free Cash Flow | — | — | 5.00M |
| Rev Growth | +17.4% | +17.4% | +21.8% |
| Debt/Equity | 20.86 | 20.86 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |